Methotrexate-Ebeve solution 50mg / 5ml, 1 bottle

Acute lymphocytic leukemia, lymphogranulomatosis, head and neck cancer (squamous cell), lung, breast; testicular and ovarian tumors; chorionepithelioma, soft tissue sarcoma, osteosarcoma, Ewing's sarcoma; retinoblastoma; trophoblastic disease (mono- and combination therapy), autoimmune diseases, psoriasis (with refractoriness to other types of treatment).

Inside, before eating, without chewing, drinking water; i / m, i / v (bolus, infusion), i / a, intrathecal (subarachnoid). Doses are selected individually, depending on the disease, general condition and blood picture of the patient. Doses above 100 mg / m2 of body surface are administered only intravenously drip (solution or concentrate is pre-diluted with 5% glucose solution to a level of 10 mg (500-1000 ml) and protected by calcium folinate. Intrathecal - 0.2-0.5 mg / kg (8-12 mg / m2) every 2-3 days; after the disappearance (or reduction) of symptoms, the interval between injections increases to 1 week, then up to 1 month; prophylactically - every 6-8 weeks In psoriasis, psoriatic arthritis , autoimmune diseases - 10-25 mg orally, weekly (it is also possible to intravenously or intramuscularly in the same dose); the initial dose is 2.5-5 mg, then the dose is increased to 7.5-25 mg / week (no more than 30 mg / week).

1 tablet contains methotrexate 2.5; 5 or 10 mg; in polypropylene bottles of 50 pcs., in a box 1 bottle.

1 ml solution for injection - 10 mg; in vials of 1 or 5 ml, in a box 1 bottle.

1 ml of concentrate for preparation of infusions - 100 mg; in bottles of 5, 10 or 50 ml, in a box 1 bottle.

Hypersensitivity, impaired liver and kidney function; bone marrow hypoplasia, leukopenia, thrombocytopenia, anemia; infectious diseases; ulcers in the oral cavity and gastrointestinal tract, postoperative conditions, pregnancy, breastfeeding.